About 520 million people worldwide between the ages of 15 and 49 are living with HSV-2, the virus most commonly associated with genital herpes. That works out to roughly 13% of the global population in that age range. In the United States specifically, the prevalence is similar: about 12% of people aged 14 to 49 have HSV-2, based on CDC national survey data from 2015–2016.
Those numbers are large, but they only tell part of the story. Most people with HSV-2 don’t know they have it, testing can be unreliable, and transmission risk varies widely depending on circumstances.
Global and U.S. Prevalence
The World Health Organization estimates that 520 million people aged 15 to 49 were living with HSV-2 as of 2020. Of those, only about 205 million (roughly 5% of the same age group) experienced at least one symptomatic episode that year. That means the majority of people carrying HSV-2 either had no outbreaks at all or had symptoms so mild they didn’t recognize them as herpes.
In the U.S., the CDC’s National Health and Nutrition Examination Survey (NHANES) found an overall HSV-2 prevalence of 11.9% among people aged 14 to 49. Applied to the U.S. population in that age range, that translates to tens of millions of people. Because the virus stays in the body for life, prevalence climbs with age. Older adults above the survey’s 49-year cutoff likely have even higher rates, meaning the true number of Americans with HSV-2 is substantially larger than headline figures suggest.
Why Most People Don’t Know They Have It
The gap between infection numbers and diagnosis numbers is enormous. Most people with HSV-2 have no symptoms or symptoms mild enough to be mistaken for something else: a razor bump, an ingrown hair, minor irritation. The WHO puts it plainly: many people aren’t aware they have the infection and can pass the virus to others without knowing.
This isn’t just anecdotal. Of the 520 million people estimated to carry HSV-2 globally, fewer than half experienced even a single recognizable outbreak in 2020. The rest were completely asymptomatic that year. Some may have occasional mild outbreaks they never connect to herpes. Others may never have a noticeable symptom in their lifetime, yet they can still shed the virus intermittently and transmit it to partners.
Blood Test Accuracy and False Positives
If you’re thinking about getting tested, the accuracy of the test matters more than most people realize. The standard approach is a blood test that looks for antibodies to HSV-2 (called an IgG test), but not all test platforms perform equally.
A 2024 study in the Journal of Clinical Microbiology compared three widely used testing systems and found striking differences. Two of them had sensitivity above 97% and specificity above 98%, meaning they correctly identified both positive and negative samples the vast majority of the time. The third, made by DiaSorin, had noticeably lower accuracy: about 94.5% sensitivity and 94.2% specificity. That gap sounds small, but at a population level it creates a serious false-positive problem.
In a hypothetical group of 100,000 people tested, the best-performing platform would produce about 440 false positives. The DiaSorin platform would produce over 5,100. Given that only about 12% of the U.S. population actually has HSV-2, the math gets uncomfortable: nearly one in three positive results from the DiaSorin system would be wrong. The problem is concentrated at low-positive index values. About 21% of DiaSorin HSV-2 results in the low-positive range (index values below 3.0) turned out to be false positives.
If you receive a positive HSV-2 blood test with a low index value, a confirmatory test using a different method is worth pursuing before drawing conclusions.
Transmission Between Partners
For people in relationships where one partner has HSV-2 and the other doesn’t, the annual transmission risk is lower than many expect. In a large clinical trial studying couples in exactly this situation, 3.6% of susceptible partners acquired HSV-2 over an eight-month period when no antiviral medication was used. When the infected partner took daily antiviral suppressive therapy, that rate dropped to 1.9%, cutting the risk roughly in half.
Condom use reduces risk further on top of antiviral therapy. The combination of daily suppressive medication and consistent condom use brings annual transmission rates down to low single digits. These numbers apply to heterosexual couples; transmission dynamics can differ for other pairings, and the direction of transmission (male to female versus female to male) also affects risk, with female partners generally being more susceptible.
The Connection to HIV Risk
One of the most clinically significant consequences of HSV-2 is its effect on vulnerability to HIV. A large meta-analysis published in The Lancet Infectious Diseases found that people with existing HSV-2 infection were about 2.7 times more likely to acquire HIV compared to those without HSV-2. Among people at already elevated risk for HIV, the increase was smaller but still meaningful, roughly doubling the odds.
The risk was highest in people who had recently acquired HSV-2. A new infection was associated with a 4.7-fold increase in HIV susceptibility, likely because the immune response and genital inflammation are most intense in the early period after infection. This connection is one reason public health organizations view HSV-2 control as relevant to HIV prevention efforts, particularly in regions where both infections are common.
Putting the Numbers in Context
HSV-2 is one of the most common sexually transmitted infections on the planet, carried by roughly one in eight adults of reproductive age in the U.S. and one in eight globally. The vast majority of those people are undiagnosed because they either have no symptoms or don’t recognize the ones they have. Routine STI screening panels typically do not include herpes testing unless you specifically request it, which further widens the gap between actual prevalence and diagnosed cases.
The practical takeaway is that HSV-2 is far more common than most people assume, and the stigma around it is disproportionate to its medical impact for most carriers. For the majority of people, HSV-2 is a manageable, often asymptomatic condition. The situations where it carries serious health consequences, such as increased HIV susceptibility or transmission to newborns during childbirth, are real but specific, and they’re the primary reasons public health agencies continue to track and study the virus.